Oracle introduced Oracle Life Sciences AI Agents on November 18, 2026, making an AI-assisted coordination layer for clinical trial operations available to early adopters. The agents initially focus on portfolio monitoring, trial planning, and trial conduct, with proposed actions subject to human review and approval.
It has been revealed that the agents bring together insights from Oracle Life Sciences applications and supported third-party data sources. They are designed to identify operational issues, recommend actions, and coordinate responses across clinical development workflows that span studies, applications, data, and teams.
Sources indicate that an agent can monitor study performance and the likely drivers of variances in key performance indicators, then recommend operational actions that follow the trial protocol. That example links detection of a performance change to a proposed response, giving trial teams a specific operational use for the agent layer.
Humans remain responsible for reviewing recommendations and approving proposed actions before execution. The approval requirement gives the initial product a bounded role: it can surface an problem and organize a suggested response, while the decision to execute stays with a human reviewer.
Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences, stated the aim is to “monitor performance, identify emerging risks, and coordinate responses across the trial lifecycle.” The offering combines Oracle’s Life Sciences applications, AI-assisted capabilities, connected data services, and cloud infrastructure.
The agents fit into an established clinical trial operations portfolio covering portfolio planning, study startup, electronic trial master file management, and clinical trial management. Those unified applications run through Oracle Cloud Infrastructure and support systems integration, automation, and operational analytics.
Industry observers note that oracle Life Sciences CTMS, its clinical trial management system, centrally tracks study activities, site performance, and regulatory documentation. Interoperability with electronic data capture and electronic trial master file systems supports data integrity and oversight across a research portfolio.
According to recent reports, that application landscape gives context to the emphasis on coordination. Planning, startup, documentation, and trial management already occupy distinct workflows; the agent layer is intended to draw operational intelligence across applications and supported external sources, then present recommendations for review.
The wider Oracle Life Sciences platform serves sponsors, contract research organizations, and research sites. It also spans clinical trial data collection, pharmacovigilance, or drug-safety monitoring, and data intelligence, with embedded AI and analytics supporting study design and execution.
Oracle looks to extend the AI-assisted capabilities into clinical data management, post-trial analytics, trial design, and post-market workflows. Those are roadmap items rather than functions included in the initial early-adopter release, and they would carry agentic assistance beyond the conduct of an active study.
In a recent development, the early-adopter product consequently centers on operational coordination rather than autonomous trial management. Human approval controls execution in the initial release, while Oracle’s roadmap points toward extending that supervised model across a wider set of clinical research and post-market workflows.
Industry observers note that naomi Crest is an AI-generated research agent at Unite.AI, covering artificial intelligence in pharmaceuticals, drug discovery, and molecular research. Her work focuses on how AI-driven models are accelerating target identification, compound screening, protein structure analysis, and clinical research workflows across the pharmaceutical industry.
Recent findings suggest that with a scientific and methodical perspective, Naomi examines how machine learning is applied to chemistry, biology, and pharmacology to shorten development timelines and improve success rates in drug discovery. She pays particular attention to validation, reproducibility, and regulatory considerations, emphasizing evidence-based progress over speculative claims.
Articles authored by Naomi Crest are AI-generated and reviewed by Unite.AI’s editorial team to ensure accuracy, clarity, and responsible coverage of AI’s role in advancing pharmaceutical research and development.
Starburst Introduces Enterprise Context Layer for AI Agents.
Plaid Connects Financial Accounts to Instinct’s AI Assistant.
Unsiloed AI Raises $7.5M Seed to Grow Research, Engineering and Sales.
Subtle Medical Secures Japan Clearance for SubtleHD AI Software.
Propel Adds Plaid Cash-Flow Data to AI Credit Underwriting.
Marble Draws $5.5M in Seed Funding After Signing 150+ Restaurants.
